Healthcare / Medical Instruments & SuppliesShanghai
$8.70
-0.08 (-0.91%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-49.0M · quality 45.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.6B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-20.1%
↓Gross Margin
31.0%
↓Debt/Equity
0.58
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-6.4%
FCF CAGR
—
FCF margin
-8.2%
FCF / Net income
0.23x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $686.0M · net income $-245.6M · FCF $-56.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $686.0M | $686.0M | $775.7M | $894.5M | $837.2M |
| Net Income | $-245.6M | $-245.6M | $-59.7M | $-65.5M | $34.5M |
| EBITDA | $-99.5M | $-99.5M | $68.2M | $74.7M | $154.5M |
| EPS | -0.47 | -0.47 | -0.11 | -0.12 | 0.07 |
| Gross Margin | 31.0% | 31.0% | 37.3% | 42.4% | 46.3% |
| Operating Margin | -13.8% | -13.8% | -4.1% | 6.2% | 12.5% |
| Net Margin | -35.8% | -35.8% | -7.7% | -7.3% | 4.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.58 | 0.58 | 0.36 | 0.30 | 0.35 |
| Current Ratio | 0.78 | 0.78 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-56.6M | $-56.6M | $-49.0M | $-9.0M | $8.5M |
| Returns | |||||
| ROE | -20.1% | -20.1% | -4.0% | -4.2% | 2.0% |
| Valuation | |||||
| P/E | — | — | — | — | 148.29 |
| EV/EBITDA | — | — | 54.28 | 60.55 | 32.72 |
| P/B | 3.73 | 3.73 | 2.36 | 2.72 | 2.99 |
| Growth & Yield | |||||
| Revenue Growth | -11.6% | -11.6% | -13.3% | 6.8% | — |
| EPS Growth | -327.3% | -327.3% | 8.3% | -271.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+44.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.11 → -0.47
Residual
+44.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.